HCV Treatment
Boosted Danoprevir Improves Response in Prior Null Responders
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 19 April 2011 08:09
- Written by Liz Highleyman
Nearly 90% of genotype 1b prior non-responder hepatitis C patients treated with ritonavir-boosted danoprevir plus pegylated interferon/ribavirin experienced early virological response at week 12, but breakthrough reached 50% for those with genotype 1a. 
EASL 2011: Monoclonal Antibody Bavituximab Well-Tolerated by HIV/HCV Coinfected People
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 15 April 2011 14:37
- Written by Peregrine
An experimental monoclonal antibody that inhibits HCV replication was safe and well-tolerated in a clinical trial of HIV positive people coinfected with chronic hepatitis C, researchers reported at EASL 2011.
EASL 2011: Once-Daily BI 201335 Ups Response to Interferon for Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 15 April 2011 05:47
- Written by Liz Highleyman
Boerhinger Ingelheim's experimental HCV protease inhibitor BI 201335 added to pegylated interferon and ribavirin improved sustained response rates for both treatment-naive and treatment-experienced genotype 1 patients, researchers reported at EASL 2011. 
EASL 2011: Pegylated Interferon Lambda Boosts Response with Few Side Effects
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 15 April 2011 06:54
- Written by Bristol-Myers Squibb
Hepatitis C patients taking an experimental interferon formulation -- pegylated interferon lambda -- had higher rates of rapid and early virological response, with fewer flu-like symptoms and blood cell deficiencies, according to a report at EASL 2011.
EASL 2011: BMS-790052 + Pegylated Interferon/Ribavirin Works Well for First HCV Treatment
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 12 April 2011 14:11
- Written by Liz Highleyman
About 90% of treatment-naive genotype 1 hepatitis C patients achieved sustained response at 12 weeks post-treatment using the experimental HCV protease inhibitor BMS-790052 plus pegylated interferon/ribavirin, researchers reported at EASL 2011. 
More Articles...
- EASL 2011: BMS-790052/BMS-650032 Combo Cures Hepatitis C without Interferon
- EASL 2011: First Sustained Response Data for HCV Polymerase Inhibitor Mericitabine
- EASL 2011: Polymerase Inhibitor PSI-7977 Works with Interferon or Companion Drug
- EASL 2011: Telaprevir Improves HCV Cure Rates Regardless of IL28B Status
Web Design and Development by